Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study.

Youn H. Kim,H. Miles Prince,Sean Whittaker,Steven M. Horwitz,Madeleine Duvic,Julia Scarisbrick,Pietro Quaglino,Pier Luigi Zinzani,Pascal Wolter,Oliver Bechter,Yinghui Wang,Maria Corinna Palanca-Wessels,Kenneth W. Wood,Martha Li,Yi Liu,Hui-Min Lin,Meredith Little,Hadi Danaee,William L. Trepicchio,Reinhard Dummer

Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study.

2017

7517Background: The Phase 3 ALCANZA study showed significant, durable responses with CD30-directed antibody-drug conjugate BV vs PC of methotrexate (MTX) or bexarotene (Bex) for CD30-positive (CD30...

Keywords:

Physical therapy
Brentuximab vedotin
Medicine
Methotrexate
CD30
in patient
Oncology
Internal medicine
Bexarotene
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations